A growing body of evidence has shed light on the role of the hemostatic pathway and its components in the pathogenesis of multiple sclerosis (MS), particularly in enhancing and sustaining neuroinflammation.
Objective:
To review the clinical, experimental, and neuroimaging evidence supporting the role of different components of the hemostatic pathway in the pathogenesis of neuroinflammation in MS and discuss their translational potential as disease biomarkers and therapeutic targets.
Methods:
A literature search for most relevant articles from 1956 to 2020 was conducted in PubMed and Scopus.
Results:
Hemostasis components appear to be involved in different key events of neuroinflammation in MS including mononuclear cell diapedesis, microglia activation, and neuronal damage.
Conclusion:
The findings on the interplay between hemostatic and thrombotic molecular pathways in the pathogenesis of neuroinflammation in MS open new opportunities for developing novel biomarkers for disease monitoring and prognosis, as well as novel therapeutic targets.
BjelobabaISavicDLavrnjaI.Multiple sclerosis and neuroinflammation: The overview of current and prospective therapies. Curr Pharm Des2017; 23(5): 693–730.
2.
FoleyJHConwayEM.Cross talk pathways between coagulation and inflammation. Circ Res2016; 118: 1392–1408.
3.
Saluk-BijakJDziedzicABijakM.Pro-thrombotic activity of blood platelets in multiple sclerosis. Cells2019; 8: 110.
4.
ElzeyBDTianJJensenRJ, et al. Platelet-mediated modulation of adaptive immunity: A communication link between innate and adaptive immune compartments. Immunity2003; 19(1): 9–19.
5.
HerringJMMcMichaelMASmithSA.Microparticles in health and disease. J Vet Intern Med2013; 27: 1020–1033.
6.
Marcos-RamiroBOliva NacarinoPSerrano-PertierraE, et al. Microparticles in multiple sclerosis and clinically isolated syndrome: Effect on endothelial barrier function. BMC Neurosci2014; 15: 110.
7.
GroenKMaltbyVEScottRJ, et al. Concentrations of plasma-borne extracellular particles differ between multiple sclerosis disease courses and compared to healthy controls. Mult Scler Relat Disord2020; 45: 102446.
8.
JyWMinagarAJimenezJJ, et al. Endothelial microparticles (EMP) bind and activate monocytes: Elevated EMP-monocyte conjugates in multiple sclerosis. Front Biosci2004; 9: 3137–3144.
9.
VosCMGeurtsJJMontagneL, et al. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol Dis2005; 20(3): 953–960.
10.
YatesRLEsiriMMPalaceJ, et al. Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex. Ann Neurol2017; 82(2): 259–270.
11.
MaggiPMacriSMGaitánMI, et al. The formation of inflammatory demyelinated lesions in cerebral white matter. Ann Neurol2014; 76(4): 594–608.
12.
LeeNJHaSKSatiP, et al. Spatiotemporal distribution of fibrinogen in marmoset and human inflammatory demyelination. Brain2018; 141: 1637–1649.
13.
MarikCFeltsPABauerJ, et al. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity. Brain2007; 130(Pt11): 2800–2815.
14.
IInoueAKohCS, et al. Fibrin deposition in the central nervous system correlates with the degree of Theiler’s murine encephalomyelitis virus-induced demyelinating disease. J Neuroimmunol1997; 77(2): 185–194.
15.
AkassoglouKAdamsRABauerJ, et al. Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc Natl Acad Sci U S A2004; 101(17): 6698–6703.
16.
AdamsRABauerJFlickMJ, et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med2007; 204(3)): 571–582.
17.
DavalosDRyuJKMerliniM, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun2012; 3: 1227.
18.
RyuJKPetersenMAMurraySG, et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat Commun2015; 6: 8164.
19.
RyuJKRafalskiVAMeyer-FrankeA, et al. Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol2018; 19: 1212–1223.
20.
MagliozziRHametnerSFacchianoF, et al. Iron homeostasis, complement, and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis. Ann Clin Transl Neurol2019; 6(11): 2150–2163.
21.
FrigerioSArianoCBernardiG, et al. Cerebrospinal fluid thrombomodulin and sVCAM-1 in different clinical stages of multiple sclerosis patients. J Neuroimmunol1998; 87(1–2): 88–93.
22.
GobelKKraftPPankratzS, et al. Prothrombin and factor X are elevated in multiple sclerosis patients. Ann Neurol2016; 80(6): 946–951.
23.
ZiliottoNBaroniMStraudiS, et al. Coagulation factor XII levels and intrinsic thrombin generation in multiple sclerosis. Front Neurol2018; 9: 245.
24.
HanMHHwangSIRoyDB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature2008; 451: 1076–1081.
25.
ZiliottoNZivadinovRBaroniM, et al. Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis. Eur J Neurol2020; 27(2): 235–243.
26.
GobelKPankratzSAsaridouCM, et al. Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. Nat Commun2016; 7: 11626.
27.
GobelKEichlerSWiendlH, et al. The coagulation factors fibrinogen, thrombin, and factor XII in inflammatory disorders: A systematic review. Front Immunol2018; 9: 1731.
28.
BardehleSRafalskiVAAkassoglouK.Breaking boundaries-coagulation and fibrinolysis at the neurovascular interface. Front Cell Neurosci2015; 9: 354.
29.
GvericDHanemaaijerRNewcombeJ, et al. Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage. Brain2001; 124: 1978–1988.
30.
GvericDHerreraBPetzoldA, et al. Impaired fibrinolysis in multiple sclerosis: A role for tissue plasminogen activator inhibitors. Brain2003; 126(Pt7): 1590–1598.
31.
ZiliottoNBernardiFJakimovskiD, et al. Coagulation pathways in neurological diseases: Multiple sclerosis. Front Neurol2019; 10: 409.
32.
ZivkovicMStarcevic CizmarevicNLovrecicL, et al. The role of TPA I/D and PAI-1 4G/5G polymorphisms in multiple sclerosis. Dis Markers2014; 2014: 362708.
33.
NaghibalhossainiFEhyakonandehHNiksereshtA, et al. Association between MTHFR genetic variants and multiple sclerosis in a southern Iranian population. Int J Mol Cell Med2015; 4(2): 87–93.
34.
RisticSCizmarevicNSSepcicJ, et al. Angiotensin-converting enzyme insertion/deletion gene polymorphism in multiple sclerosis: A meta-analysis. Neurol Sci2016; 37(12): 1955–1959.
35.
SoonDTozerDAltmannD, et al. Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: A study of disease and lesion subtypes. Mult Scler2007; 13(7): 884–894.
36.
ChingASKuhnastBDamontA, et al. Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. Insights Imag2012; 3(1): 111–119.
37.
HerranzEGianniCLouapreC, et al. Neuroinflammatory component of gray matter pathology in multiple sclerosis. Ann Neurol2016; 80(5): 776–790.
38.
BlasiFOliveiraBLRietzTA, et al. Multisite thrombus imaging and fibrin content estimation with a single whole-body PET scan in rats. Arterioscler Thromb Vasc Biol2015; 35(10): 2114–2121.
39.
RyuJKDavalosDAkassoglouK.Fibrinogen signal transduction in the nervous system. J Thromb Haemost2009; 7(Suppl. 1): 151–154.
40.
PetersenMARyuJKAkassoglouK.Fibrinogen in neurological diseases: Mechanisms, imaging and therapeutics. Nat Rev Neurosci2018; 19(5): 283–301.
41.
SolNLeursCEVeld StrijbisEM, et al. Blood platelet RNA enables the detection of multiple sclerosis. Mult Scler J Exp Transl Clin2020; 6(3): 946784.
42.
ZiliottoNLambertiNManfrediniF, et al. Functional recovery in multiple sclerosis patients undergoing rehabilitation programs is associated with plasma levels of hemostasis inhibitors. Mult Scler Relat Disord2020; 44: 102319.
